---
id: transplant-infections_116
category: special-populations
tags: [solid-organ-transplant, HSCT, timeline, donor-derived, prophylaxis]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Transplant Infections

**Q:** What is the timeline of infections post-transplant, key pathogens by transplant type, prophylaxis strategies, and approach to donor-derived infections?

**A:**

## TIMELINE OF INFECTIONS POST-TRANSPLANT

**Mnemonic: "0-1-6" (0-1 month, 1-6 months, >6 months)**

| **Time Period** | **Key Infections** | **Mechanism** |
|-----------------|-------------------|---------------|
| **<1 Month** | **Surgical/nosocomial:**<br>Surgical site infections<br>Healthcare-associated infections (CLABSI, CAUTI, VAP)<br>**Donor-derived infections** | Neutropenia (HSCT), surgical complications, ICU stay |
| **1-6 Months** | **Opportunistic infections:**<br>**CMV** (peak 1-4 months)<br>**PCP** (if no prophylaxis)<br>**BK virus** (kidney transplant)<br>**Aspergillus**<br>**EBV → PTLD** | **Peak immunosuppression** |
| **>6 Months** | **Community-acquired:**<br>**Encapsulated bacteria** (S. pneumoniae)<br>**Cryptococcus**<br>**Endemic fungi** (Histoplasma, Coccidioides)<br>**West Nile virus, CMV** (if increased immunosuppression) | Chronic immunosuppression OR rejection treatment |

**Key Point:** **1-6 months = peak risk for opportunistic infections** (CMV, PCP, Aspergillus)

---

## SOLID ORGAN TRANSPLANT (SOT) INFECTIONS

### **CMV (Cytomegalovirus) - #1 Opportunistic Infection Post-SOT**

**Risk Stratification:**
- **Highest risk:** Donor CMV+ / Recipient CMV- (D+/R-) - **40-70% risk**
- **Moderate risk:** Recipient CMV+ (R+) - reactivation
- **Lowest risk:** Donor CMV- / Recipient CMV- (D-/R-)

**CMV Syndromes:**
- **CMV syndrome:** Fever, leukopenia, thrombocytopenia, transaminitis
- **Tissue-invasive disease:** Pneumonitis, colitis, hepatitis, retinitis

**Diagnosis:** **CMV PCR (viral load)** (quantitative)

**Prophylaxis (D+/R-):**
- **Valganciclovir** 900 mg PO daily (adjusted for renal function) x **3-6 months**
- **Alternative:** IV ganciclovir (if unable to take PO)

**Treatment:**
- **Valganciclovir** 900 mg PO BID x 14-21 days (mild-moderate)
- **IV ganciclovir** 5 mg/kg IV q12h x 14-21 days (severe disease)

**Key Point:** **CMV D+/R- = highest risk** (prophylaxis x 3-6 months with valganciclovir)

---

### **BK VIRUS (Polyomavirus) - Kidney Transplant**

**BK Nephropathy (BKVN):**
- **Risk:** 1-10% of kidney transplant recipients
- **Timing:** 3-12 months post-transplant

**Clinical:** Acute kidney injury, graft dysfunction

**Diagnosis:**
- **BK viremia:** BK PCR >10,000 copies/mL (high risk for nephropathy)
- **Biopsy:** Intranuclear viral inclusions ("decoy cells")

**Treatment:**
- **Reduce immunosuppression** (primary strategy - no effective antivirals)
- Consider **cidofovir** (off-label, limited evidence) OR **leflunomide**

**Key Point:** **BK virus = kidney transplant** (reduce immunosuppression to clear virus)

---

### **PCP (Pneumocystis jirovecii Pneumonia)**

**Prophylaxis (ALL SOT Recipients):**
- **TMP-SMX 1 DS daily** OR **TMP-SMX 1 SS daily** x **6-12 months**
- **Lifelong if:** Lung transplant OR ongoing rejection treatment

**Alternative (Sulfa Allergy):**
- **Dapsone** 100 mg PO daily (check G6PD)
- **Atovaquone** 1500 mg PO daily
- **Inhaled pentamidine** 300 mg monthly (least preferred)

**Key Point:** **TMP-SMX = PCP + Toxoplasma prophylaxis** (all SOT recipients)

---

### **TOXOPLASMA - Heart Transplant**

**Risk:** Heart transplant (D+/R-) - **50% risk**

**Prophylaxis:**
- **TMP-SMX 1 DS daily** x **3-6 months** (covers PCP + Toxo)

**Key Point:** **Toxoplasma prophylaxis = heart transplant** (D+/R-)

---

### **ASPERGILLUS - Lung Transplant**

**Risk:** **Highest in lung transplant** (10-15%)

**Prophylaxis:**
- **Voriconazole** 200 mg PO BID OR **Itraconazole** 200 mg PO BID x **3-6 months**

**Key Point:** **Lung transplant = highest Aspergillus risk** (voriconazole prophylaxis)

---

### **EBV → PTLD (Post-Transplant Lymphoproliferative Disorder)**

**Risk Factors:**
- **EBV-seronegative recipient** (highest risk)
- **Heavy immunosuppression** (T-cell depleting agents - ATG, alemtuzumab)

**Clinical:** Lymphadenopathy, mass lesions (GI, CNS, lungs)

**Diagnosis:** **EBV PCR** (viral load), biopsy (B-cell proliferation)

**Treatment:**
1. **Reduce immunosuppression** (RIS)
2. **Rituximab** (anti-CD20) 375 mg/m² weekly x 4 doses
3. **Chemotherapy** (if refractory)

**Key Point:** **EBV PTLD = reduce immunosuppression + rituximab**

---

## HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) INFECTIONS

### **Timeline:**

| **Phase** | **Timing** | **Key Infections** |
|-----------|------------|-------------------|
| **Pre-Engraftment** | Day 0-30 | **Neutropenia** (bacteria, Candida)<br>**HSV reactivation**<br>**Conditioning-related toxicity** |
| **Post-Engraftment** | Day 30-100 | **CMV reactivation** (peak)<br>**Aspergillus**<br>**HHV-6 encephalitis**<br>**Acute GVHD** |
| **Late Phase** | >Day 100 | **VZV reactivation**<br>**Encapsulated bacteria** (if chronic GVHD)<br>**PCP** (if chronic GVHD on immunosuppression) |

**Key Point:** **HSCT day 30-100 = CMV reactivation risk** (weekly monitoring)

---

### **CMV Reactivation (HSCT)**

**Risk Factors:**
- **Allogeneic HSCT** (especially if R+ or D+/R-)
- **Acute GVHD** or **T-cell depletion**

**Monitoring:**
- **CMV PCR (weekly) from day 0 to day 100** post-HSCT

**Pre-Emptive Therapy (if CMV viremia detected):**
- **Valganciclovir** 900 mg PO BID (adjusted for renal function)
- **IV ganciclovir** 5 mg/kg IV q12h (if unable to take PO)

**Key Point:** **Weekly CMV PCR monitoring** (day 0-100) → pre-emptive therapy if positive

---

### **HHV-6 Encephalitis**

**Risk:** Allogeneic HSCT (day 14-60)

**Clinical:** Altered mental status, seizures, amnesia

**Diagnosis:** **HHV-6 PCR (CSF)** (>1000 copies/mL)

**Treatment:** **Foscarnet** 60 mg/kg IV q8h OR **ganciclovir** 5 mg/kg IV q12h

**Key Point:** **HHV-6 encephalitis = allogeneic HSCT** (day 14-60 post-transplant)

---

## DONOR-DERIVED INFECTIONS

**Key Pathogens:**
- **Bacteria:** Bacteremia (donor bloodstream infection)
- **Viruses:** **HIV, hepatitis B/C, HTLV, WNV, rabies, LCMV**
- **Fungi:** **Candida, Aspergillus** (donor lung → recipient pneumonia)
- **Parasites:** **Toxoplasma** (donor heart → recipient dissemination), **Strongyloides, Chagas**

**Prevention:**
- **Donor screening:** HIV, HBV, HCV, HTLV, CMV, EBV, Syphilis
- **Risk assessment:** Social history (travel, exposures), organ-specific cultures

**Key Point:** **Unexplained fever/illness in multiple recipients from same donor** = consider donor-derived infection

---

## PROPHYLAXIS SUMMARY BY TRANSPLANT TYPE

| **Transplant** | **CMV Prophylaxis** | **PCP Prophylaxis** | **Antifungal Prophylaxis** | **Other** |
|----------------|---------------------|---------------------|----------------------------|-----------|
| **Kidney** | Valganciclovir x 3-6 months (D+/R-) | TMP-SMX x 6-12 months | - | BK monitoring |
| **Heart** | Valganciclovir x 3-6 months (D+/R-) | **TMP-SMX x 6-12 months** (Toxo + PCP) | - | Toxo prophylaxis (D+/R-) |
| **Lung** | Valganciclovir x 3-6 months (D+/R-) | TMP-SMX x 12 months | **Voriconazole x 3-6 months** | Aspergillus prophylaxis |
| **Liver** | Valganciclovir x 3 months (D+/R-) | TMP-SMX x 6-12 months | - | - |
| **HSCT (allo)** | Pre-emptive (weekly PCR monitoring) | TMP-SMX (after engraftment → 6 months) | Fluconazole OR posaconazole | HSV prophylaxis (acyclovir) |

**Key Point:** **TMP-SMX = universal PCP prophylaxis** (all SOT + HSCT)

---

**Clinical Pearls:**
- **Timeline: 0-1 month (nosocomial), 1-6 months (opportunistic), >6 months (community)**
- **CMV = #1 opportunistic infection post-SOT** (D+/R- highest risk)
- **Valganciclovir prophylaxis x 3-6 months** (CMV D+/R-)
- **TMP-SMX = PCP + Toxoplasma prophylaxis** (all SOT recipients)
- **BK virus = kidney transplant** (reduce immunosuppression)
- **Lung transplant = Aspergillus risk** (voriconazole prophylaxis)
- **HSCT: Weekly CMV PCR day 0-100** → pre-emptive therapy
- **HHV-6 encephalitis = allogeneic HSCT** (day 14-60)
- **EBV PTLD = reduce immunosuppression + rituximab**
- **Donor-derived infections:** HIV, HBV, HCV, WNV, rabies, Toxoplasma, Strongyloides

**Media:** None

**Sources:** [AST 2024 - Transplant ID guidelines], [IDSA 2024 - SOT infections]
